This bill accelerates the timeline for two major Medicare drug cost provisions that were part of the 2022 Inflation Reduction Act. First, it moves up the implementation of changes to Medicare prescription drug out-of-pocket spending caps by one year, shifting the threshold adjustments from 2025 to 2024. Second, it expedites the Medicare drug price negotiation program by two years, moving the initial negotiations from 2026 to 2024 and subsequent negotiation rounds forward accordingly. The bill affects Medicare beneficiaries who would see cost relief arrive sooner than originally planned, as well as pharmaceutical companies that would begin price negotiations earlier. No specific federal funding amounts are mentioned, as this legislation primarily involves timing adjustments to existing programs rather than new appropriations.
Take Action
Your position
Add a comment
to comment on this bill.
Annotate the text
Highlight any passage on the Summary or Full Text tab to attach a note. Annotations appear on the Annotations tab.